• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Prolonged viral replication in patients with hematologic malignancies hospitalized with COVID-19.

作者信息

Garcia-Vidal Carolina, Puerta-Alcalde Pedro, Mateu Aina, Cuesta-Chasco Genoveva, Meira Fernanda, Lopera Carlos, Monzo Patricia, Santos-Bravo Marta, Duenas Gerard, Chumbita Mariana, Garcia-Pouton Nicole, Gaya Anna, Bodro Marta, Herrera Sabina, Mosquera Mar, Fernandez-Aviles Francesc, Martinez Jose Antonio, Mensa Josep, Gine Eva, Marcos Maria Angeles, Soriano Alex

机构信息

Department of Infectious Diseases, Hospital Clinic of Barcelona-IDIBAPS, University of Barcelona, Barcelona.

Department of Internal Medicine, Hospital Universitari Mutua Terrassa, Terrassa.

出版信息

Haematologica. 2022 Jul 1;107(7):1731-1735. doi: 10.3324/haematol.2021.280407.

DOI:10.3324/haematol.2021.280407
PMID:35295080
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9244835/
Abstract
摘要

相似文献

1
Prolonged viral replication in patients with hematologic malignancies hospitalized with COVID-19.新冠病毒肺炎住院血液系统恶性肿瘤患者中病毒的持续复制
Haematologica. 2022 Jul 1;107(7):1731-1735. doi: 10.3324/haematol.2021.280407.
2
Long and persistent COVID-19 in patients with hematologic malignancies: from bench to bedside.血液恶性肿瘤患者的长程和持续性 COVID-19：从基础到临床。
Curr Opin Infect Dis. 2022 Aug 1;35(4):271-279. doi: 10.1097/QCO.0000000000000841. Epub 2022 Jul 5.
3
Managing patients with hematological malignancies during COVID-19 pandemic.在新冠疫情期间管理血液系统恶性肿瘤患者
Expert Rev Hematol. 2020 Aug;13(8):787-793. doi: 10.1080/17474086.2020.1787147. Epub 2020 Jul 12.
4
Poor outcome and prolonged persistence of SARS-CoV-2 RNA in COVID-19 patients with haematological malignancies; King's College Hospital experience.血液系统恶性肿瘤的COVID-19患者中SARS-CoV-2 RNA的不良预后和长期持续存在；国王学院医院的经验。
Br J Haematol. 2020 Sep;190(5):e279-e282. doi: 10.1111/bjh.16935. Epub 2020 Aug 10.
5
COVID-19 in patients with hematologic malignancy.血液恶性肿瘤患者中的 COVID-19 感染。
Blood. 2022 Jul 21;140(3):236-252. doi: 10.1182/blood.2021012251.
6
Antiviral treatment or mAbs for persistent SARS-COV-2 infection in patients with hematologic malignancies: A case series.血液系统恶性肿瘤患者持续性SARS-CoV-2感染的抗病毒治疗或单克隆抗体：病例系列
J Med Virol. 2023 Jun;95(6):e28865. doi: 10.1002/jmv.28865.
7
High mortality with High false negative rate: COVID-19 infection in patients with hematologic malignancies.高死亡率与高假阴性率：血液系统恶性肿瘤患者的新型冠状病毒肺炎感染情况
Leuk Res. 2021 Jul;106:106582. doi: 10.1016/j.leukres.2021.106582. Epub 2021 Apr 24.
8
Severe COVID-19 in patients with hematological cancers presenting with viremia.血液系统癌症患者出现病毒血症的重症 COVID-19。
Ann Oncol. 2021 Oct;32(10):1297-1300. doi: 10.1016/j.annonc.2021.07.002. Epub 2021 Jul 13.
9
SARS-CoV-2 infection and mortality in pediatric patients with hematological malignancies and solid tumors.血液系统恶性肿瘤和实体瘤儿科患者中的新型冠状病毒2型感染及死亡率
Pediatr Hematol Oncol. 2023 May;40(4):429-432. doi: 10.1080/08880018.2022.2120937. Epub 2022 Sep 12.
10
Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study.立陶宛血液系统恶性肿瘤患者的 BNT162b2 COVID-19 mRNA 疫苗免疫原性和早期临床结局：一项全国前瞻性队列研究。
Lancet Haematol. 2021 Aug;8(8):e583-e592. doi: 10.1016/S2352-3026(21)00169-1. Epub 2021 Jul 2.

引用本文的文献

1
Co-infections during SARS-CoV-2 infection in hematologic patients and cell therapy recipients in the omicron era: a Spanish hematopoietic stem cell transplantation and cell therapy group study.奥密克戎时代血液学患者和细胞治疗接受者感染新型冠状病毒期间的合并感染：西班牙造血干细胞移植和细胞治疗组研究
BMC Infect Dis. 2025 Jul 25;25(1):944. doi: 10.1186/s12879-025-11302-w.
2
Is COVID-19 Still a Threat? An Expert Opinion Review on the Continued Healthcare Burden in Immunocompromised Individuals.新冠病毒仍是威胁吗？免疫功能低下个体持续的医疗负担专家意见综述。
Adv Ther. 2025 Feb;42(2):666-719. doi: 10.1007/s12325-024-03043-0. Epub 2024 Dec 16.
3

本文引用的文献

1
Viral Culture Confirmed SARS-CoV-2 Subgenomic RNA Value as a Good Surrogate Marker of Infectivity.病毒培养证实了 SARS-CoV-2 亚基因组 RNA 值是感染性的良好替代标志物。
J Clin Microbiol. 2022 Jan 19;60(1):e0160921. doi: 10.1128/JCM.01609-21. Epub 2021 Oct 20.
2
Chronic Asymptomatic Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection in the Immunocompromised Patient: New Challenges and Urgent Needs.免疫功能低下患者的慢性无症状严重急性呼吸综合征冠状病毒2（SARS-CoV-2）感染：新挑战与迫切需求
Clin Infect Dis. 2022 Feb 11;74(3):553. doi: 10.1093/cid/ciab538.
3
Prolonged and severe SARS-CoV-2 infection in patients under B-cell-depleting drug successfully treated: A tailored approach.
Outcomes of Antiviral Retreatment for Immunocompromised Hosts With Prolonged Severe Acute Respiratory Syndrome Coronavirus 2 Polymerase Chain Reaction Positivity: A Multicenter Australian Retrospective Case Series.
免疫功能低下宿主严重急性呼吸综合征冠状病毒2聚合酶链反应长期阳性的抗病毒治疗结果：一项澳大利亚多中心回顾性病例系列研究
Open Forum Infect Dis. 2024 Aug 7;11(8):ofae449. doi: 10.1093/ofid/ofae449. eCollection 2024 Aug.
4
Successful CAR-T cell therapy in a refractory MCL patient with bacterial, fungal and COVID-19 infection: a case report.一名患有细菌、真菌和新冠病毒感染的难治性套细胞淋巴瘤患者的成功嵌合抗原受体T细胞疗法：病例报告
Front Transplant. 2023 Sep 19;2:1238494. doi: 10.3389/frtra.2023.1238494. eCollection 2023.
5
Reply to the Comment on: "Dexamethasone treatment for COVID-19 is related to increased mortality in hematologic malignancy patients: results from the EPICOVIDEHA Registry".对关于《地塞米松治疗新冠病毒病与血液系统恶性肿瘤患者死亡率增加相关：EPICOVIDEHA注册研究结果》评论的回复
Haematologica. 2024 Oct 1;109(10):3457-3458. doi: 10.3324/haematol.2024.285875.
6
Real-Life Comparison of Antivirals for SARS-CoV-2 Omicron Infection in Patients With Hematologic Malignancies.血液系统恶性肿瘤患者感染新型冠状病毒奥密克戎变异株后抗病毒药物的真实世界比较
Influenza Other Respir Viruses. 2024;18(3):e13264. doi: 10.1111/irv.13264.
7
The Burden of COVID-19 in Adult Patients With Hematological Malignancies: A Single-center Experience After the Implementation of Mass-vaccination Programs Against SARS-CoV-2.COVID-19 给血液系统恶性肿瘤成年患者带来的负担：大规模 SARS-CoV-2 疫苗接种计划实施后的单中心经验。
In Vivo. 2023 Nov-Dec;37(6):2743-2754. doi: 10.21873/invivo.13385.
8
Clinical and immunological characteristics of prolonged SARS-CoV-2 Omicron infection in hematologic disease.血液系统疾病中新型冠状病毒奥密克戎变异株长期感染的临床和免疫学特征
Blood Cancer J. 2023 Sep 5;13(1):133. doi: 10.1038/s41408-023-00897-5.
9
Treatment of COVID-19 during the Acute Phase in Hospitalized Patients Decreases Post-Acute Sequelae of COVID-19.住院患者急性期新冠病毒病的治疗可减少新冠病毒病急性后遗症。
J Clin Med. 2023 Jun 20;12(12):4158. doi: 10.3390/jcm12124158.
10
Prevalence and Clinical Outcome of Omicron Breakthrough Infection in Patients With Hematologic Disease: A Prospective Observational Cohort Study.血液系统疾病患者中奥密克戎突破性感染的患病率及临床结局：一项前瞻性观察队列研究
Hemasphere. 2023 Jun 6;7(6):e905. doi: 10.1097/HS9.0000000000000905. eCollection 2023 Jun.
使用B细胞耗竭药物的患者中严重急性呼吸综合征冠状病毒2型（SARS-CoV-2）感染的长期及成功治疗：一种定制化方法
Int J Infect Dis. 2021 Jun;107:247-250. doi: 10.1016/j.ijid.2021.04.068. Epub 2021 Apr 24.
4
SARS-CoV-2 evolution during treatment of chronic infection.慢性感染治疗过程中 SARS-CoV-2 的进化。
Nature. 2021 Apr;592(7853):277-282. doi: 10.1038/s41586-021-03291-y. Epub 2021 Feb 5.
5
Intractable Coronavirus Disease 2019 (COVID-19) and Prolonged Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Replication in a Chimeric Antigen Receptor-Modified T-Cell Therapy Recipient: A Case Study.嵌合抗原受体修饰 T 细胞治疗受体中难治性 2019 年冠状病毒病（COVID-19）和持续严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）复制：病例研究。
Clin Infect Dis. 2021 Aug 2;73(3):e815-e821. doi: 10.1093/cid/ciab072.
6
Duration of Culturable SARS-CoV-2 in Hospitalized Patients with Covid-19.新型冠状病毒肺炎住院患者中可培养的严重急性呼吸综合征冠状病毒2的持续时间。
N Engl J Med. 2021 Feb 18;384(7):671-673. doi: 10.1056/NEJMc2027040. Epub 2021 Jan 27.
7
COVID-19 in Immunocompromised Hosts: What We Know So Far.免疫功能低下宿主中的 COVID-19：目前我们已知的情况。
Clin Infect Dis. 2021 Jan 27;72(2):340-350. doi: 10.1093/cid/ciaa863.
8
Case Study: Prolonged Infectious SARS-CoV-2 Shedding from an Asymptomatic Immunocompromised Individual with Cancer.病例研究：一名患有癌症的无症状免疫功能低下个体长期感染性严重急性呼吸综合征冠状病毒2（SARS-CoV-2）脱落。
Cell. 2020 Dec 23;183(7):1901-1912.e9. doi: 10.1016/j.cell.2020.10.049. Epub 2020 Nov 4.
9
Persistence and Evolution of SARS-CoV-2 in an Immunocompromised Host.严重急性呼吸综合征冠状病毒2型在免疫功能低下宿主中的持续存在与演变
N Engl J Med. 2020 Dec 3;383(23):2291-2293. doi: 10.1056/NEJMc2031364. Epub 2020 Nov 11.
10
SARS-CoV-2 positive virus culture 7 weeks after onset of COVID-19 in an immunocompromised patient suffering from X chromosome-linked agammaglobulinemia.一名患有X染色体连锁无丙种球蛋白血症的免疫功能低下患者在感染COVID-19发病7周后，SARS-CoV-2病毒培养呈阳性。
J Infect. 2021 Mar;82(3):414-451. doi: 10.1016/j.jinf.2020.10.025. Epub 2020 Oct 27.